Syngulora
About
What does Syngulora do?
Syngulora is developing an AI-powered platform designed to accelerate and optimize scientific research and development processes. Their technology aims to assist researchers in areas such as drug discovery, materials science, and synthetic biology by automating experimental design, data analysis, and hypothesis generation. The platform targets R&D departments in pharmaceutical, biotech, and chemical industries.
What is Syngulora's revenue?
StartupHub estimates Syngulora's annual revenue at $93K (range $43K to $213K, 29% confidence), based on comparable companies in the sector.
What is Syngulora's valuation?
StartupHub estimates Syngulora's effective valuation at $3.6M (range $2.5M to $6.0M, 10% confidence), based on comparable companies in the sector.
How much funding has Syngulora raised?
Syngulora has raised a total of $1M in funding. The most recent round on record is Seed.
What industry does Syngulora operate in?
Syngulora operates in AI Infrastructure, Drug Discovery, Materials Science, Synthetic Biology, Foundation Model, Generative AI.
Clinical Trial Discovery by ENSCORE.
Eccoscience is a startup focused on developing AI-powered solutions for scientific research and discovery.
AI-powered platform for clinical trial patient recruitment and data management.
SomaIQ drafts the interpretation and patient explanation for your review, reducing a 90-minute task to five.
Ultimed develops an AI-powered platform to streamline medical imaging analysis and reporting for radiologists.
Discover innovative AI therapeutics at fibrotherapeutics.ai, enhancing patient care and advancing health technology.
Explore cutting-edge bio technology solutions with AI, launching soon.
AI-powered platform for tissue analysis and diagnostics.
An entrant is a company tagged Drug Discovery whose domain was first registered in the window, counted from registry records in the StartupHub directory. 1 of them registered in the last 30 days. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.